

## Nordic Casemix Centre - Case #507

### New DRG in MDC12 for outpatient stereotactic radiotherapy or demanding isotope therapy cases

2017-01-17 16:16 - Kristiina Kahur

<b>Status:</b> Accepted	<b>Start date:</b> 2017-01-17
<b>Priority:</b> Normal	<b>Spent time:</b> 0.00 hour
<b>Assignee:</b> Kristiina Kahur	
<b>Category:</b>	
<b>Target version:</b> Expert Group 2017	
<b>Initiator:</b> Finland	<b>Target year:</b> 2018
<b>MDC:</b> MDC12	<b>Owner / responsible:</b> National organisations
<b>Target Grouper:</b> FIN	<b>Old forum status:</b>

**Description**

**Problem**

DRG 912A Male reproductive system tumor, radiotherapy, short therapy in Finnish grouper is meant for cases of male reproductive tumor treated with radiotherapy. It includes four different groups of procedures: radiotherapy (PROCPROP 90T05), radiotherapy with large shaped fields (90T06), stereotactic radiotherapy or demanding isotope therapy (90T07), special demanding isotope therapy (90T08).

The number of cases in 912A is high (ca 27 000 in 2014 and ca 31 000 in 2015), so is the variation coefficient, 182% and 201% respectively. That was the indication for further analysis.

**Analysis**

The mean cost of DRG 912A is 175 EUR in 2014 and 193 in 2015 ranging between 30 and 5 820 EUR, and 30 and 14 889 EUR respectively.

The cases with PROCPROP 90T07 differ from the rest of the group and have the mean cost ca ten times higher compared to the DRG 912A average, i.e. 193 EUR vs ca 1 800 EUR in 2015.

Also the variation coefficient of cases with PROCPROP 90T07 is much lower than all cases in DRG 912A (34% versus 201% in 2015) and shows the cost homogeneity of selected cases.

**Suggestion**

Based on the cost analysis we suggest create separate DRG for outpatient cases with PROCPROP 90T07.

**DRG change**

The cases with main diagnosis from MDC12 and procedure code with PROCPRO 90T07 will be grouped in a new DRG 912C. Name of the new DRG should be Male reproductive system tumor, stereotactic radiotherapy or demanding isotope therapy, short therapy.

**Technical changes**

Appendix 2. The technical changes may contain mistakes and have to be used with caution.

**Cost analysis**

Appendix 1. Cost analysis is based on five university hospital data of 2015, grouped with Finnish 2017 grouper, and data of 2014, grouped with Finnish 2016 grouper.

## History

#1 - 2017-03-06 15:26 - Kristin Dahlen

- File Case 507\_Norwegian DRG solution.xlsx added

In Norway we have already implemented a split for this cases.

DRG 852N Brachytherapy for prostate cancer (covers both inpatient and outpatient cases) and DRG 852X Brachytherapy for tumor, outpatient.

This DRGs are part of a logic concerning both the radiotherapy and the planning of radiotherapy.  
See the enclosed excel sheet for the Norwegian DRG logic.

#### #2 - 2017-04-26 17:11 - Martti Virtanen

2107-03-13 Expert group.

The change was accepted for Finland. Norwegian or other versions are not changed.

#### #3 - 2017-04-26 17:12 - Martti Virtanen

- File *Technical changes case #507.xlsx* added

2017-04-26 Martti Virtanen

Technical changes for combined NordDRG version.

Changes affect only NordDRG Fin.

The new rule needs to be placed before the rules for DRG 912A

#### #4 - 2018-01-09 14:55 - Martti Virtanen

- Status changed from Active to Accepted

#### Files

---

MDC12_912A_St.tactic rad.therapy_short_therapy_Appendix1.xlsx	12.9 KB	2017-01-17	Kristiina Kahur
MDC12_912A_St.tactic rad.therapy_short_therapy_Appendix2.xlsx	15.2 KB	2017-01-17	Kristiina Kahur
Case 507_Norwegian DRG solution.xlsx	14.8 KB	2017-03-06	Kristin Dahlen
Technical changes case #507.xlsx	17.7 KB	2017-04-26	Martti Virtanen